Lv6
3060 积分 2024-09-06 加入
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
11天前
已完结
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
3个月前
已完结
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
3个月前
已完结
Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy
3个月前
已完结
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy
3个月前
已完结
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
6个月前
已完结
新药非临床研究一般考虑及案例分析
8个月前
已完结
PD-1_PD-L1抗体临床前药效标志物和CAR-T细胞临床前药效评价的特点及检测方法
8个月前
已完结
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
9个月前
已完结
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
9个月前
已完结
皖公网安备34019202002308
